Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04871282 · ClinicalTrials.gov registry record · Phase 2
A Study of AL102 in Patients With Progressing Desmoid Tumors
A Phase 2 study of Desmoid Tumor and Desmoid, sponsored by Immunome.
- Active
- Registry status
- Phase 2
- Development phase
- 198
- Enrollment target
- 20
- Study locations
NCT04871282 is a Phase 2 study of Desmoid Tumor and Desmoid that is active but no longer recruiting, run by Immunome. The registered enrollment target is 198 participants, above the 40-participant average among 4 other Desmoid Tumor trials with a reported enrollment target (395% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT04871282, a Phase 2 study of Desmoid Tumor and Desmoid, is active but no longer recruiting, sponsored by Immunome.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 198 participants
- Enrollment target
- 20
- Study locations
Study Summary
The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG AL102
Study Locations (20)
California
- City of Hope - Duarte
- Sarcoma Oncology Research Center - Santa Monica
- University of California at Los Angeles Hematology/Oncology - Santa Monica
- Stanford University Medical Center - Stanford
Pennsylvania
- Jefferson University Hospital - Philadelphia
- Fox Chase Cancer Center - Philadelphia
- University of Pittsburgh Medical Center, Hillman Cancer Center - Pittsburgh
Missouri
- Jefferson City Medical Group - Jefferson City
- Washington University - St Louis
New York
- Columbia University Irving Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cleveland Clinic - Cleveland
- Ohio State University Wexner Medical Center - Columbus
Arizona
- Mayo Clinic - Pheonix
Florida
- Mayo Clinic - Jacksonville
Illinois
- NorthShore University Health System - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2021-03-30 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04871282
The ClinicalTrials.gov registry entry for NCT04871282 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 40-participant average among 4 other Desmoid Tumor trials with a reported enrollment target (395% higher). The listed sponsor is Immunome, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Desmoid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04871282 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Pennsylvania, Missouri.
Frequently Asked Questions
What is clinical trial NCT04871282 about?
NCT04871282 is a clinical study titled "A Study of AL102 in Patients With Progressing Desmoid Tumors". The current study is designed to evaluate the efficacy and safety of AL102 in patients with progressive desmoid tumors.
What is the current status of trial NCT04871282?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 198 participants. The study started on 2021-03-30. Estimated completion is 2026-10.
What conditions does trial NCT04871282 study?
This clinical trial studies the following conditions: Desmoid Tumor, Desmoid.
What interventions are being tested in trial NCT04871282?
The interventions under investigation include: Placebo (OTHER), AL102 (DRUG).
Who is sponsoring clinical trial NCT04871282?
This trial is sponsored by Immunome, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04871282 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Desmoid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Cryoablation and Nirogacestat for Desmoid Tumor
RECRUITING · Phase 2
-
Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
COMPLETED · Phase 2
-
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
COMPLETED · Phase 2
-
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.